{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-006784","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2026-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.861089+00:00","generated_at":"2026-05-16T02:52:17.394826+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ProPhase Labs initiates sale process for BE-Smart esophageal cancer test; updates on COVID-19 receivable collections","bullets":["Initiated potential sale or strategic partnership for BE-Smart, a CLIA/CAP-accredited LDT for esophageal cancer risk; outreach to >70 acquirers.","Crown Medical Collections: >60% of aggregate claims are from commercial payors that partially reimbursed, implying higher recovery rates.","Laboratory subsidiaries are in Chapter 11; legacy COVID-19 testing receivables being addressed via Crown Medical Collections initiative."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-006784","json":"https://secwatch.observer/filing/0001493152-26-006784.json","markdown":"https://secwatch.observer/filing/0001493152-26-006784.md","text":"https://secwatch.observer/filing/0001493152-26-006784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315226006784/0001493152-26-006784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315226006784/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:52:17.394826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}